The company added that details of the settlement are confidential. In March 2024, a jury found that Dexcom’s G6 glucose monitors infringed one of three of Abbott’s patents, but jurors couldn’t reach a ...
Insulet Corporation PODD recently made its Omnipod 5 automated insulin delivery system commercially available in five more ...
In a report released yesterday, William Plovanic from Canaccord Genuity maintained a Buy rating on Dexcom (DXCM – Research Report), with a ...
Dexcom (DXCM) has received a new Buy rating, initiated by Wells Fargo analyst, Larry Biegelsen.Stay Ahead of the Market:Discover outperforming ...
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by its strong product portfolio. A ...
Acton, Massachusetts-based Insulet touts Omnipod 5 as the number one insulin pump for new users in Europe. It remains the top ...
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its ...
Dexcom on Tuesday announced its first generative AI feature for its Stelo biosensor that gives users a personalized weekly report about their glucose. The company has been building a generative AI ...
North Chicago-based Abbott announced last month it reached a settlement agreement with Dexcom over all outstanding patent disputes relating to their glucose monitoring products, which estimate blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results